Loading...
Wakamoto Pharmaceutical Co.,Ltd.
4512.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥297.00
¥0.00(0.00%)
Wakamoto Pharmaceutical Co.,Ltd. (4512.T) Financial Performance & Income Statement Overview
Review Wakamoto Pharmaceutical Co.,Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.66%
↑ 0.66%
Operating Income Growth
-134.15%
↓ 134.15%
Net Income Growth
-40.86%
↓ 40.86%
Operating Cash Flow Growth
-451.95%
↓ 451.95%
Operating Margin
-5.88%
↓ 5.88%
Gross Margin
46.50%
↑ 46.50%
Net Profit Margin
0.83%
↑ 0.83%
ROE
0.54%
↑ 0.54%
ROIC
-3.53%
↓ 3.53%
Wakamoto Pharmaceutical Co.,Ltd. (4512.T) Income Statement & Financial Overview
Review Wakamoto Pharmaceutical Co.,Ltd.'s (4512.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.98B | $2.00B | $1.93B | $1.88B |
| Cost of Revenue | $1.06B | $1.06B | $1.09B | $956.04M |
| Gross Profit | $922.67M | $931.71M | $839.59M | $928.50M |
| Gross Profit Ratio | $0.47 | $0.47 | $0.44 | $0.49 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.04B | $996.60M | $1.03B | $1.02B |
| Operating Expenses | $1.04B | $996.60M | $1.03B | $1.02B |
| Total Costs & Expenses | $2.10B | $2.06B | $2.11B | $1.97B |
| Interest Income | $1.21M | $0.00 | $0.00 | $0.00 |
| Interest Expense | $325000.00 | $146000.00 | $245000.00 | $166000.00 |
| Depreciation & Amortization | $113.51M | $110.68M | -$4.94M | $100.63M |
| EBITDA | $251.65M | $240.34M | -$192.24M | $35.83M |
| EBITDA Ratio | $0.13 | $0.12 | -$0.10 | $0.02 |
| Operating Income | -$116.23M | -$64.88M | -$187.30M | -$89.38M |
| Operating Income Ratio | -$0.06 | -$0.03 | -$0.10 | -$0.05 |
| Other Income/Expenses (Net) | $253.78M | $194.39M | -$7.34M | $24.41M |
| Income Before Tax | $137.55M | $129.51M | -$194.64M | -$64.96M |
| Income Before Tax Ratio | $0.07 | $0.06 | -$0.10 | -$0.03 |
| Income Tax Expense | $53.99M | $6.92M | -$64.28M | -$53.61M |
| Net Income | $83.56M | $122.59M | -$130.36M | -$11.35M |
| Net Income Ratio | $0.04 | $0.06 | -$0.07 | -$0.006 |
| EPS | $2.41 | $3.53 | -$3.76 | -$0.33 |
| Diluted EPS | $2.41 | $3.53 | -$3.75 | -$0.33 |
| Weighted Avg Shares Outstanding | $34.71M | $34.71M | $34.65M | $34.71M |
| Weighted Avg Shares Outstanding (Diluted) | $34.71M | $34.71M | $34.75M | $34.71M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan